(MASS) 908 Devices - Overview
Stock: Handheld, Desktop, Analyzer, Spectrometry, Bioprocess
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 78.8% |
| Relative Tail Risk | -16.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 135.29 |
| Character TTM | |
|---|---|
| Beta | 0.674 |
| Beta Downside | -0.067 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.85% |
| CAGR/Max DD | -0.16 |
Description: MASS 908 Devices December 31, 2025
908 Devices Inc. (NASDAQ:MASS) is a commercial-stage technology firm that designs and sells purpose-built handheld and desktop mass-spectrometry instruments for life-science research, bioprocessing, pharma/biopharma, forensic analysis, and related markets. Its flagship products include the MX908 handheld mass spectrometer, the Rebel desktop analyzer for real-time bioprocess monitoring, and the Maverick optical in-line analyzer that tracks glucose, lactate, and biomass in mammalian cell cultures. The portfolio also features Maven (online bioprocess control), Trace C2 (methanol/ethanol monitoring for fermentation), and the ZipChip plug-and-play high-resolution separation platform.
Based on the latest SEC filings, MASS reported FY 2023 revenue of roughly $31 million, representing a year-over-year increase of about 18 % and a gross margin of ~62 %. The company’s cash runway extends through Q4 2025 assuming current burn rates, but it remains dependent on continued adoption of its devices in large-scale biomanufacturing projects.
Key sector drivers include the accelerating shift toward continuous bioprocessing, which is projected by industry analysts to grow at a CAGR of ~12 % through 2030, and the increasing regulatory emphasis on real-time release testing (RTRT) that favors inline analytical technologies like Maverick. A macro-level risk is the potential slowdown in biotech capital expenditures if financing conditions tighten, which could compress demand for high-cost analytical equipment.
For a deeper quantitative assessment, you might explore ValueRay’s analyst toolkit to see how MASS stacks up against peers on valuation and growth metrics.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -4.13m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 2.33 > 1.0 |
| NWC/Revenue: 179.5% < 20% (prev 174.2%; Δ 5.26% < -1%) |
| CFO/TA -0.14 > 3% & CFO -27.2m > Net Income -4.13m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.1m) vs 12m ago 4.13% < -2% |
| Gross Margin: 49.35% > 18% (prev 0.53%; Δ 4882 % > 0.5%) |
| Asset Turnover: 31.23% > 50% (prev 26.79%; Δ 4.44% > 0%) |
| Interest Coverage Ratio: -2.85 > 6 (EBITDA TTM -37.5m / Interest Expense TTM 14.8m) |
Altman Z'' -6.24
| A: 0.54 (Total Current Assets 144.9m - Total Current Liabilities 41.5m) / Total Assets 190.9m |
| B: -1.19 (Retained Earnings -227.5m / Total Assets 190.9m) |
| C: -0.23 (EBIT TTM -42.3m / Avg Total Assets 184.6m) |
| D: -4.17 (Book Value of Equity -227.4m / Total Liabilities 54.6m) |
| Altman-Z'' Score: -6.24 = D |
Beneish M -3.30
| DSRI: 0.55 (Receivables 11.0m/16.7m, Revenue 57.6m/47.8m) |
| GMI: 1.07 (GM 49.35% / 52.57%) |
| AQI: 0.60 (AQ_t 0.20 / AQ_t-1 0.33) |
| SGI: 1.21 (Revenue 57.6m / 47.8m) |
| TATA: 0.12 (NI -4.13m - CFO -27.2m) / TA 190.9m) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of MASS shares?
Over the past week, the price has changed by +3.80%, over one month by +21.30%, over three months by -16.03% and over the past year by +156.86%.
Is MASS a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MASS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 52.7% |
| Analysts Target Price | 10 | 52.7% |
| ValueRay Target Price | 6.3 | -4.3% |
MASS Fundamental Data Overview February 02, 2026
P/B = 1.6862
Revenue TTM = 57.6m USD
EBIT TTM = -42.3m USD
EBITDA TTM = -37.5m USD
Long Term Debt = 4.35m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 481.0k USD (from shortTermDebt, last quarter)
Debt = 4.35m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -58.4m USD (from netDebt column, last quarter)
Enterprise Value = 120.7m USD (228.4m + Debt 4.35m - CCE 112.1m)
Interest Coverage Ratio = -2.85 (Ebit TTM -42.3m / Interest Expense TTM 14.8m)
EV/FCF = -4.25x (Enterprise Value 120.7m / FCF TTM -28.4m)
FCF Yield = -23.53% (FCF TTM -28.4m / Enterprise Value 120.7m)
FCF Margin = -49.28% (FCF TTM -28.4m / Revenue TTM 57.6m)
Net Margin = -7.17% (Net Income TTM -4.13m / Revenue TTM 57.6m)
Gross Margin = 49.35% ((Revenue TTM 57.6m - Cost of Revenue TTM 29.2m) / Revenue TTM)
Gross Margin QoQ = 52.52% (prev 48.89%)
Tobins Q-Ratio = 0.63 (Enterprise Value 120.7m / Total Assets 190.9m)
Interest Expense / Debt = 340.2% (Interest Expense 14.8m / Debt 4.35m)
Taxrate = 21.0% (US default 21%)
NOPAT = -33.4m (EBIT -42.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.49 (Total Current Assets 144.9m / Total Current Liabilities 41.5m)
Debt / Equity = 0.03 (Debt 4.35m / totalStockholderEquity, last quarter 136.3m)
Debt / EBITDA = 1.56 (negative EBITDA) (Net Debt -58.4m / EBITDA -37.5m)
Debt / FCF = 2.06 (negative FCF - burning cash) (Net Debt -58.4m / FCF TTM -28.4m)
Total Stockholder Equity = 139.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.24% (Net Income -4.13m / Total Assets 190.9m)
RoE = -2.96% (Net Income TTM -4.13m / Total Stockholder Equity 139.8m)
RoCE = -29.32% (EBIT -42.3m / Capital Employed (Equity 139.8m + L.T.Debt 4.35m))
RoIC = -23.88% (negative operating profit) (NOPAT -33.4m / Invested Capital 139.8m)
WACC = 8.24% (E(228.4m)/V(232.7m) * Re(8.40%) + (debt cost/tax rate unavailable))
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.49%
Fair Price DCF = unknown (Cash Flow -28.4m)
EPS Correlation: -0.30 | EPS CAGR: 11.86% | SUE: 0.33 | # QB: 0
Revenue Correlation: 20.87 | Revenue CAGR: -3.23% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.09 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.26 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+23.5% | Growth Revenue=+18.7%